MORRIS PLAINS, N.J., April 13, 2009 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that nine presentations on the Company’s potential products will occur at the 100th Annual Meeting of the American Association for Cancer Research (AACR), April 18 - 22, 2009, in Denver, Colorado. Five of the presentations will be on product candidates created by the Company, and its majority-owned subsidiary, IBC Pharmaceuticals, Inc.'s proprietary protein engineering platform technology known as Dock-and-Lock (DNL). The schedule and meeting places for the poster sessions, together with the abstract and poster board numbers are listed below:
